Amid Regulatory and Reimbursement Difficulties, Some Encouraging Advancements for Personalized Rx

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

Pharma Slowly Adapting to Complexities and Challenges of Developing Personalized Medicine

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

No articles associated with the most recent, published issue of the magazine, or none have been affiliated with magazine sections.

Amid Regulatory and Reimbursement Difficulties, Some Encouraging Advancements for Personalized Rx

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

Pharma Slowly Adapting to Complexities and Challenges of Developing Personalized Medicine

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

No articles associated with the most recent, published issue of the magazine, or none have been affiliated with magazine sections.